# CYTOSORBENTS CORPORATION (CTSO) · Edgar & Edgarette company card

> Cytosorbents (CTSO) grew revenue 4.1% in FY2025 to $37 million, operating margin -39.8% against a 1.2% median for surgical & medical instruments & apparatus, equity 13.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1175151 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CTSO) · [JSON](https://www.pops4.com/boards/company/CTSO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $37M |
| Revenue growth, 1 year | 4.1% |
| Revenue growth per year | -3.7% |
| Operating margin | -39.8% (prior year -46.2%) |
| Net margin | -22.1% |
| Operating cash flow | −$12M |
| Capital spending | $164,000 |
| Free cash flow | −$13M |
| Cash | $6M |
| Long-term debt | $17M |
| Total assets | $44M |
| Total equity | $6M |
| Equity ÷ assets | 13.4% |
| Return on equity | -138.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -23.5 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -2.09 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -39.8% in FY2025; revenue is hard to predict: its 80% range is ±48%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $37.1M (FY2025), total debt $16.7M. Experience: revenue up 4.1% on the year, down 3.7% a year over 4 years; operating margin -39.8%, up from -46.2%. Soundness: equity 13.4% of assets, return on equity -138.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $22.2M and $63.2M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $20.7M to $68.1M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -39.8% against a 1.2% median; growth 4.1% against 11.6%.

Range logged 2026-09-24, receipt 6d51f5f54565c7d8, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-07-06 ([filing](https://www.sec.gov/Archives/edgar/data/1175151/000110465926080741/0001104659-26-080741-index.htm))

## Recent filings

- 8-K · filed 2026-09-23 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1175151/000110465926109814/0001104659-26-109814-index.htm)
- 8-K · filed 2026-09-08 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1175151/000110465926105901/0001104659-26-105901-index.htm)
- 8-K · filed 2026-08-14 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1175151/000110465926097092/0001104659-26-097092-index.htm)
- 8-K · filed 2026-08-07 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/0001104659-26-092691-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1175151/000110465926092039/0001104659-26-092039-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1175151/000110465926092006/0001104659-26-092006-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001175151.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1175151

## Cite

POPS4, Edgar & Edgarette: CYTOSORBENTS CORPORATION (CTSO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CTSO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.